Soleno Therapeutics has withdrawn its European drug application. This decision stems from its acquirer, Neurocrine Biosciences, prioritizing the United States market. The drug, Vykat XR, treats a rare genetic disorder. Neurocrine’s CEO confirmed the focus remains on the U.S. launch. This move aligns with a trend of delayed European launches amid U.S. pricing policy shifts.